[Research Progress of Granulocytic Myeloid-derived Suppressor Cells in Non-small Cell Lung Cancer]
Chaodan Yang1,2,3, Rui Zhu4, Yuting Zhang5
1School of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
Abstract:
Granulocytic myeloid-derived suppressor cells (G-MDSCs) are one of the main subgroups of MDSCs, which are widely enriched in most cancers. It can inhibit the killing function of T-lymphocyte through the expression of arginase-1 (Arg-1) and reactive oxygen species (ROS), reshape the tumor immune microenvironment, and promote the occurrence and development of tumors. In recent years, more and more studies have found that G-MDSCs are significantly correlated with the prognosis and immunotherapy efficacy of patients with non-small cell lung cancer, and the use of drugs specifically targeting the recruitment, differentiation and function of G-MDSCs can effectively inhibit tumor progression. This article reviews the immunosuppressive effect of G-MDSCs in non-small cell lung cancer and the progress of related pathway targeting drugs. .
Insights
Granulocytic myeloid-derived suppressor cells (G-MDSCs) suppress anti-tumor immunity in non-small cell lung cancer. Targeting G-MDSCs shows promise for improving cancer prognosis and immunotherapy efficacy.
Area of Science:
- Immunology
- Oncology
Background:
- Granulocytic myeloid-derived suppressor cells (G-MDSCs) are key immune suppressors in cancer.
- G-MDSCs inhibit T-lymphocyte function via arginase-1 (Arg-1) and reactive oxygen species (ROS).
- They reshape the tumor immune microenvironment, promoting tumor growth.
Approach:
- This review summarizes the immunosuppressive roles of G-MDSCs in non-small cell lung cancer (NSCLC).
- It examines the progress of drugs targeting G-MDSC-related pathways.
- Focus is on G-MDSC recruitment, differentiation, and function.
Key Points:
- G-MDSCs are enriched in most cancers, including NSCLC.
- G-MDSC levels correlate significantly with NSCLC patient prognosis and immunotherapy response.
- Targeting G-MDSCs can effectively inhibit tumor progression.
Conclusions:
- G-MDSCs play a critical role in the immunosuppressive tumor microenvironment of NSCLC.
- Developing drugs targeting G-MDSCs offers a promising strategy for NSCLC treatment.
- Further research into G-MDSC-targeted therapies is warranted for improved patient outcomes.
